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PrognosisAbstract Introduction: Cytokeratin fragment 21.1 (CYFRA 21.1) assay detects a serum fragment
of cytokeratin 19 (CK19) and is employed in the diagnosis and management of lung cancer, partic-
ularly of squamous cell histotype. Breast carcinoma has been demonstrated to express CK19 frag-
ments in the primary and metastatic lesions and CK19 mRNA is detectable in peripheral blood
from patients affected by breast cancer. Aim of the work: The aim of the present study was to eval-
uate the clinical significance of serum CYFRA21-1 in patients with breast cancer by analyzing the
correlation between serum CYFRA21-1 titers, clinicopathological factors and prognosis in compar-
ison with serum CA15.3 and CEA tested in the same samples. Subjects and methods: This study
included 60 breast cancer patients and 25 healthy females as control group. Three blood samples
were drawn from each patient, before surgery, two weeks after surgery and after 6 cycles of
chemotherapy. One blood sample was drawn from each subject of control group. Serum was sep-
arated and kept frozen till used for estimation of CYFRA21-1 by enzyme linked immunosorbent
assay (ELISA) and serum CA15.3 and CEA by immunoradiometric assay (IRMA). Results: Serum
CYFRA21-1 was highly elevated in breast cancer patients than in controls and was significantly
associated with tumor size, clinical stage and axillary lymph node involvement. Serum
CYFRA21-1 was superior to CA15.3 and CEA as a diagnostic marker for breast cancer using
ROC curve analysis. Higher levels of serum CYFRA21-1 and CA15.3 were significantly associated
with poor prognosis in primary breast cancer patients. Conclusions: The measurement of serum
CYFRA 21-1 in breast cancer patients may be useful for detecting disease relapse and for assessing
surgical and chemotherapeutic efficacy. Further prospective studies using greater number of
patients are required to confirm our findings.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ue, El-
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Breast cancer is the most common cancer and second cause of
cancer-death among females in most Western countries where
there is an overall lifetime risk of >10% of developing breast
cancer.1 Although diagnosis by screening mammography is
believed to be responsible for the significant decline in breast
cancer mortality, the limitations of mammography are well
recognized, especially for women with premenopausal breast
cancer.2 Thus, alternative approaches to breast cancer detec-
tion are clearly needed for improving diagnosis/prognosis.3
The clinical usefulness of serum tumor markers for breast
cancer surveillance has not yet been established. Indeed, until
sufficient data on this subject are obtained, the American Soci-
ety of Clinical Oncology (ASCO) recommends against the rou-
tine use of even well-known antigens such as carcinoembryonic
antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) after
primary treatment or in monitoring responses to treatment.4
Therefore, it is clearly a worthwhile goal to find a reliable
serum tumor marker with high sensitivity and high specificity
for breast cancer.5
It has been demonstrated that breast cancer cells express
fragments of cytokeratin-19, which are one of the various
kinds of cytokeratins comprising the intermediate filaments
of the cytoskeleton. Serum fragments of cytokeratin-19 can
be detected using anti-CYFRA21-1 antibody. Most of the epi-
topes that are detectable by clinically useful tumor markers
such as CEA, CA 15-3, CA 19-9, and alpha-fetoprotein are
glycoproteins shed from the cell surface. CYFRA 21-1 is
unique in that its epitope is a polypeptide, which is most likely
released following cell death.6 Elevated levels of serum
CYRFA 21-1 titers have been observed in various malignan-
cies, especially in lung cancer. Healthy individuals with an
abnormal level of serum CYFRA 21-1 are quite rare.7 Patients
with nonmalignant disease also showed almost no elevation of
serum CYFRA 21-1, except in cases of cirrhosis, renal failure,
or infectious lung disease. In previous studies, 20–30% of
patients with one of these three benign diseases showed ele-
vated levels of serum CYRFA 21-1. However, little is known
about this tumor marker for breast cancer.7–9 Serum CYFRA
21-1, the most sensitive tumor marker used in monitoring non-
small cell lung cancer10,11 has been reported to be detected in
the peripheral blood from patients with metastatic breast can-
cer and proposed to be used in monitoring disease relapse and
treatment response in breast cancer patients.9
The aim of the present study was to evaluate the clinical sig-
nificance of serum CYFRA21-1 in patients with primary
breast cancer by analyzing the correlation between serum
CYFRA21-1 titers, clinicopathological factors and prognosis
in comparison with serum CA15.3 and CEA tested in the same
samples.
2. Subjects and methods
This study included 60 primary breast cancer patients and 25
healthy females. Patients were recruited from Menofiya Clini-
cal Oncology Institute, Menofiya University. A written con-
sent for participating in the study was taken from all
contributors according to the declaration of Helsinki. Patients
were subjected to preoperative evaluation including history
taking, and clinical examination to detect the site of the tumor.Radiological investigations included mammogram, abdominal
ultrasound and chest X-ray. Preoperative investigations also
included fine needle aspiration cytology (FNAC) to diagnose
the presence of malignancy. Patients were subjected to surgery
and postoperative pathological evaluation of the tumor.
Patients received 6 cycles of chemotherapy and followed up
for 15 months to assure the prognostic value of the markers.
Patients who lost follow-up were excluded from this study.
2.1. Blood samples collection
Three blood samples were drawn from each patient, before
surgery, two weeks after surgery and after 6 cycles of
chemotherapy. One blood sample was drawn from each sub-
ject of control group. Blood samples were allowed to clot for
30 min before centrifugation and centrifuged at 3000 rpm for
10 min to isolate sera. The serum was stored at 20 C until
used. Circulating serum CYFRA 21.1 was measured by
enzyme linked immunosorbent assay (ELISA) (DRG, USA)
and serum CA15.3 and CEA by immunoradiometric assay
(IRMA) (IBL, Germany) according to the manufacturer’s
instructions.
2.2. Statistical analyses
Statistical analyses were conducted using the statistical soft-
ware package of SPSS version 17 (SPSS Inc, Chicago, USA).
Quantitative data were described using minimum and maxi-
mum as well as mean and standard error. Differences between
groups were assessed by the Mann–Whitney U test for non-
parametric variables. Diagnostic performance for studied
parameters was evaluated using ROC curve analysis.
Disease-free survival (DFS) curves were plotted using the
Kaplan–Meier method. We defined DFS as the time between
the date of diagnosis and the date of unfavorable outcome
including local recurrence, distant metastasis or contralateral
breast cancer. Correlations between quantitative variables
were assessed using spearman correlation coefficient. Statisti-
cal significance was set at p 6 0.05.
3. Results
3.1. Clinicopathological characteristics of breast cancer patients
Clinicopathological characteristics of breast cancer patients
are represented in Table 1.
3.2. Serum CYFRA 21.1 in breast cancer patients
As shown in Table 2, serum CYFRA21-1 was highly elevated
in breast cancer patients before surgery than in control group,
and the difference was statistically significant (P1 = 0.003). It
was also noticed that the levels of this parameter after 2 weeks
of surgery and after 6 cycles of chemotherapy were signifi-
cantly decreased than before surgery (P2 = 0.002 and 0.001
respectively) and became within the normal control value
(P1 = 0.421 and 0.089 respectively). On comparing serum
CYFRA21-1 levels after 2 weeks of surgery with those after
6 cycles of chemotherapy, the difference was not significant
(P3 = 0.710).
Table 2 The statistical analysis of serum CYFRA21-1, CA15.3 and
Control group (n= 25) Breast cancer patien
Before surgery
CYFRA 21-1 (ng/ml)
Range 0.3–1.65 0.3–32
Mean ± SE 1.1 ± 0.092 5.72 ± 1.71
P1 0.003*
P2
P3
CA-15-3 (U/ml)
Range 5–32 7–180
Mean ± SE 16.13 ± 1.57 43.2 ± 1.96
P1 0.015*
P2
P3
CEA (ng/ml)
Range 0.4–4.2 0.8–60.5
Mean ± SE 1.86 ± 0.23 7.21 ± 2.29
P1 0.013*
P2
P3
P1: p value compared to normal control subjects.
P2: p value compared to before surgery.
P3: p value compared to after 2 weeks of surgery.
* Statistically significant at p 6 0.05.
Table 1 Clinicopathological characteristics of breast cancer
patients.
Breast cancer patients (n= 60)
Age
Mean ± SE 47.72 ± 8.92
Range 31–65
Menopausal status
Pre 25 (41.6%)
Post 35 (58.4%)
Histological grade
II 41 (68.3%)
III 19 (31.7%)
Clinical stage
II 40 (66.7%)
III 20 (33.4%)
ER status
Positive 43 (71.7%)
Negative 17 (28.3%)
PR status
Positive 39 (65%)
Negative 21 (35%)
Her-2/neu expression
Positive 17 (28.3%)
Negative 43 (71.7%)
Tumor size
65 52 (86.7%)
>5 8 (13.3%)
Axillary lymph node involvement (%)
Positive 41 (68.3%)
Negative 19 (31.7%)
Abbreviations: ER: estrogen receptor, PR: progesterone receptor,
Her-2/neu: human epidermal growth factor receptor 2.
Serum CYFRA 21-1 in women 433.3. Serum CA 15.3 in breast cancer patients
Table 2 reveals that serum levels of CA15.3 in breast cancer
patients before surgery were significantly higher than in con-
trol group (P1 = 0.015). It was also noticed that the levels
of this parameter after 2 weeks of surgery and after 6 cycles
of chemotherapy were significantly decreased than before sur-
gery (P2 = 0.004 and 0.002 respectively) and became within
the normal control value (P1 = 0.511 and 0.491 respectively).
On comparing serum CA15.3 levels after 2 weeks of surgery
with those after 6 cycles of chemotherapy, the difference was
not significant (P3 = 0.735).
3.4. Serum CEA in breast cancer patients
Table 2 shows that serum CEA levels in breast cancer patients
before surgery were significantly higher than in control group
(P1 = 0.013). We also found that CEA levels after 2 weeks of
surgery and after 6 cycles of chemotherapy were nearly within
the same range (P3 = 0.853), significantly decreased than
before surgery (P2 = 0.022 and 0.015 respectively) and
became within the normal control value (P1 = 0.539 and
0.435 respectively).
3.5. Diagnostic performance of serum CYFRA 21-1, CA 15.3
and CEA in breast cancer patients
The receiver operating characteristic curve (ROC) analysis was
used to compare the diagnostic value of serum CYFRA21-1,
CA15.3 and CEA depending on the area under the curve
(AUC). The higher AUC corresponds to a better diagnostic
test. Serum CYFRA21-1 showed significant AUC (0.921,
P< 0.001) with sensitivity (88%) and specificity (85%) at a
cutoff value 2 (ng/ml). Serum CA15.3 showed significantCEA levels in normal control subjects and breast cancer patients.
ts (n= 60)
After 2 weeks of surgery After 6 cycles of chemotherapy
0.4–1.8 0.3–1.6
1.0 ± 0.081 0.78 ± 0.065
0.421 0.089
0.002* 0.001*
0.710
8–29 6.9–26
17.01 ± 0.86 14.76 ± 0.17
0.511 0.491
0.004* 0.002*
0.735
0.6–18 0.8–19
1.98 ± 0.13 2.03 ± 0.59
0.539 0.435
0.022* 0.015*
0.853
Figure 2 Kaplan–Meier disease free survival of serum CA15.3
for breast cancer patients.
Figure 3 Kaplan–Meier disease free survival for serum CEA for
44 S.A. Ebied et al.AUC (0.818, P= 0.002) with sensitivity (70%) and specificity
(80%) at a cutoff value 30 (U/ml). Serum CEA showed signif-
icant AUC (0.738, P= 0.018) with sensitivity (60%) and
specificity (66%) at a cutoff value 4 (ng/ml). Based on these
results, serum CYFRA21-1 had higher diagnostic performance
than serum CA15.3 and serum CEA.
3.6. Prognostic value of serum CYFRA 21-1, CA 15.3 and CEA
in breast cancer patients
To study the prognostic value of these parameters, the
Kaplan–Meier survival curves were constructed. As shown in
Figs. 1–3 Kaplan–Meier analysis revealed that, patients with
elevated levels of serum CYFRA 21-1(>2 ng/ml) and
CA15.3 (>30 U/ml) than their corresponding cutoff points
had shorter disease free survival time than patients with lower
levels (P< 0.000 and P= 0.001 respectively). On the other
hand, insignificant difference between high and low levels of
serum CEA was observed (P= 0.317).
3.7. Correlation between studied parameters and patients
clinicopathological characteristics
According to Table 3, it was observed that, there was a signif-
icant positive correlation between serum CYFRA21-1 and
axillary lymph node involvement (P= 0.024), tumor size
(P= 0.031) and clinical stage (P= 0.042) while insignificant
correlation was observed with age (P= 0.532), histological
grade (P= 0.326), ER and PR status (P= 0.954 and 0.450
respectively) and Her/2neu expression (P= 0.076). On the
other hand, serum CA15.3 and serum CEA showed insignifi-
cant correlation with all studied clinic-pathological
parameters.
4. Discussion
Breast cancer is the most common neoplasm affecting women
in the Western world. Many studies are still conducted with the
purpose of finding markers that could be used for early diag-Figure 1 Kaplan–Meier disease free survival of serum
CYFRA21-1 for breast cancer patients.
breast cancer patients.nosis and/or serve as possible reliable prognostic or predictive
parameters, but with conflicting results. At present, no mark-
ers are available for an early diagnosis of breast cancer. For
surveillance of patients with diagnosed breast cancer, the most
widely used serum markers are CA 15-3 and CEA which, in
combination with other clinical parameters, could have clinical
significance.12 Serum CYFRA 21-1, the most sensitive tumor
marker used in monitoring non-small cell lung cancer10,11
has been reported to be detected in the peripheral blood from
patients with metastatic breast cancer.9
The present study showed that, serumCYFRA21-1 in breast
cancer patients before surgery was highly elevated than that in
control group. In agreement with our result Giovanella et al.7
reported that serum CYFRA21-1 increased in patients affected
by breast cancer in comparison with controls. Bidard et al.13
investigated that CYFRA 21-1 is the most commonly elevated
serum tumor marker (65% of patients) in metastatic breast can-
cer patients, supporting our result. CYFRA21-1 determines
only fragments of cytokeratin 19 (CK19). Cytokeratin 19 is a
Table 3 Correlation between studied parameters and patients
clinicopathological characteristics.
CYFRA 21-1 CA 15.3 CEA
rs P rs P rs P
Age 0.086 0.532 0.047 0.724 0.001 0.992
Axillary lymph node
involvement (%)
0.291 0.024* 0.026 0.846 0.028 0.833
Histological grade 0.129 0.326 0.049 0.721 0.005 0.968
Tumor size 0.279 0.031* 0.082 0.534 0.057 0.663
Clinical stage 0.265 0.042* 0.209 0.110 0.127 0.335
ER status 0.008 0.954 0.036 0.772 0.019 0.886
PR status 0.099 0.450 0.065 0.621 0.131 0.317
Her-2/neu expression 0.213 0.076 0.003 0.980 0.134 0.307
rs: Spearman coefficient.
* Statistically significant at p 6 0.05.
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epithelial cells. Themechanismof the release of CK19 fragments
(CYFRA21-1) is a proteolytic cleavage.During apoptosis CK19
protein is cleaved by caspase 3 and produces soluble CYFRA21-
1 fragments. When epithelial cells transformed into malignant
cells, the keratin content increased. Due to necrosis of tumor
cells, the soluble fragment CYFRA21-1 of CK19 is released into
the blood. CYFRA21-1 provides a useful marker for epithelial
malignancies, distinctly reflecting ongoing cell activity.14
In our study, we also noticed that serum CYFRA21-1 after
2 weeks of surgery significantly decreased than before surgery
and became within the normal control value. This result is sim-
ilar to that reported by Nakata et al.5 who found that the ele-
vated preoperative levels of serum CYFRA 21-1 decreased to
normal levels after curative operation. Suggesting that serum
CYFRA21-1 may be a good marker for surgical curability.
Furthermore, our results demonstrated that serum
CYFRA21-1 after 6 cycles of chemotherapy was significantly
decreased than corresponding values before surgery and
approaching normal control values. This finding is in line with
study done by Nakata et al.5 who reported the changes of
serum CYFRA 21-1 levels after chemotherapy and found that
serum CYFRA21-1 in five of seven patients with postoperative
recurrence decreased to the normal range after chemotherapy.
He also stated that, in patients with stable disease, chemother-
apy reduced the serum CYFRA 21-1 levels to approximately
20–90% of the prechemotherapy levels. These results lead us
to suggest that serum CYFRA21-1 may be a reliable marker
of chemotherapy efficacy in patient with breast cancer.
The relationship between serum CYFRA21-1 and clinico-
pathological characteristic of the disease has been investigated
in various malignancies. Holdenrieder et al.15 demonstrated
that CYFRA21-1 levels were significantly associated with clin-
ical stage in patients with lung cancer. In non-small cell lung
cancer Lee et al.16 reported that tumor size and histological
grade were correlated with CYFRA21-1 levels. In colorectal
cancer Lee 17 found that serum CYFRA21-1 was not corre-
lated with lymph node involvement, histological grade, clinical
stage or tumor size. In the present study, we found that high
levels of CYFRA21-1 in serum of breast cancer patients were
significantly correlated with tumor size. This may point to the
growth advantage for cells possessing high levels of
CYFRA21-1. This hypothesis is coincided with that reportedby Nakata et al.9 who suggested that elevated levels of
CYFRA21-1 function to promote cell growth.
Similarly, the concentration of this parameter in serum was
positively correlated with clinical stage of the disease. This
finding indicated that serum CYFRA21-1 may be considered
as a biological marker for estimating the occurrence and pro-
gression of breast cancer and reflecting an unfavorable prog-
nosis for breast cancer patients regardless of the treatment.
This correlation was proven in a previous study carried out
by Nakata et al.9 who reported that increasing serum
CYFRA21-1 was related to higher clinical stage.
Whereas axillary lymph nodes involvement is known as an
effective and independent factor in breast cancer prognosis, its
correlation with serum CYFRA21-1 can help to determine
prognosis of breast cancer. In our study, a positive correlation
was found between serum CYFRA21-1 and axillary lymph
node involvement. Since serum CYFRA21-1 was positively
correlated with clinical stage, tumor size and axillary lymph
node involvement already tested as prognostic markers may
throw light on the possibility of using this parameter as an
effective marker for the determination of breast cancer prog-
nosis. Regarding the correlation between serum CYFRA21-1
and ER, PR and Her-2/neu expression, our study showed
insignificant correlation between serum CYFRA21-1 and
ER, PR status and Her-2/neu expression. Bidard et al.13 con-
firmed our results as they found that serum CYFRA21-1 not
correlated with hormone receptors status or Her-2/neu
positivity.
CA15.3 is the mucin-1 marker that is the most widely used
serum marker in breast cancer. Currently, its main uses are in
surveillance of patients with diagnosed disease and monitoring
the treatment of patients with advanced disease.18 CA15.3 has
been implicated in cell adhesion, immunity and metastasis com-
pared with healthy breast tissue.19 In the present study serum
CA15.3 before surgery was highly elevated in patients group
than normal control group. These elevated levels of CA15.3
in breast cancer patients may be attributed to the presence of
malignant disease. This result is similar to that reported by
Ali et al.20 who reported that serum CA15.3 was significantly
elevated in breast cancer patients than in controls. Moreover,
our result showed that serum CA15.3 levels after 2 weeks of
surgery were significantly decreased than before surgery and
became within the normal control value. This result may be
due to the removal of the bulk mass of the tumor.20 After 6
cycles of chemotherapy CA15.3 significantly decreased than
corresponding values before surgery. These results mean that
serum CA15.3 plays a role in monitoring the response of breast
cancer patients to surgery and chemotherapy. These results are
supported by many previous studies.21,22
Carcinoembryonic antigen was detected in cancer and
embryonic tissue. Since CEA is rarely detected in the blood
of healthy individuals, so its elevated levels in breast cancer
patients than in normal control subjects may indicate the pres-
ence of breast carcinoma. This result is similar to that reported
by Lee et al.21 Our result is supported by Duffy et al.23 who
found that serum CEA from individuals with colorectal, gas-
tric, pancreatic and lung cancer had higher levels of CEA than
healthy individuals.
After 2 weeks of surgery and after 6 cycles of chemotherapy,
serum CEA levels were nearly within the same range, signifi-
cantly decreased than before surgery and becamewithin the nor-
mal control value. The significant decrease in CEA levels post
46 S.A. Ebied et al.2 weeks of surgery or after chemotherapy may be attributed to
the removal of the malignant mass and the effectiveness of
chemotherapy. These results indicated that serum CEA levels
may be a useful tumormarker in that it may reflect cancer status
and could be considered a reliable marker for chemotherapy
response in breast cancer patients.
The significant preoperative elevations of CYFRA21-1,
CA15.3 and CEA in serum of breast cancer patients than in
control subjects suggest the possibility of using any one of
these parameters for diagnosis of breast cancer. This directs
us to compare the diagnostic performance of these parameters.
Using ROC curve analysis, serum CYFRA21-1 showed higher
AUC, sensitivity and specificity followed by CA15.3 then
CEA. So serum CYFRA21-1 was sensitive and specific in
breast cancer diagnosis than CA15.3 and superior to CEA.
Rodriguez et al.8 examined the serum CYFRA 21-1, CEA,
and CA 15-3 titers in 40 patients with metastatic breast cancers
and found that CYFRA 21-1 was a sensitive tumor marker for
breast cancer when compared with CEA or CA 15-3, support-
ing our results. However, contrary to our results, Giovanella
et al.7 reported that serum CYFRA 21-1 was less accurate
for the evaluation of primary and recurrent breast cancer than
serum CA 15-3. The low diagnostic value of CYFRA 21-1 in
breast cancer reported by Giovanella et al.7 might be due to
some issues such as time of measurement and their higher
serum CYFRA 21-1 cutoff value (3.3 ng/ml) compared to
our cutoff value (2.0 ng/ml).
Moreover, follow-up study was made to answer the ques-
tion of whether preoperative serum CYFRA21-1, CA15.3
and CEA levels are of prognostic significance. Notably after
15 months, our results showed that breast cancer patients with
preoperative higher levels of serum CYFRA21-1 had shorter
disease free survival time and poor prognosis than patients
with lower levels. This study supports the finding that serum
CYFRA21-1 may add prognostic information to that obtained
from classical prognostic factors and be useful in detecting
early recurrence in breast cancer patients. This suggestion is
coincided with that reported by Nakata et al.5 who reported
that elevated levels of CYFRA21-1 function to promote inva-
sion and metastasis. Furthermore, we find relation between
CA15.3 and prognosis by evaluating disease free survival
(DFS) in patients group. The analysis of DFS showed that
higher levels of serum CA15.3 are significantly associated with
poor prognosis in breast cancer patients. This result is in agree-
ment with that of Di Gioia et al.22 who showed independent
prognostic value of CA15.3. Moreover, Ali et al.20 found that
CA15-3 is an important prognostic indicator and good predic-
tor for relapse. In contrast to our result Velaiutham et al.24
found that preoperative CA15.3 had no prognostic value.
Regarding serum CEA and DFS, our study demonstrated that
preoperative serum CEA failed to predict disease free survival
in primary breast cancer patients. In fact, our result is in line
with Bartsch et al.25 who reported that preoperative CEA
had no prognostic value and CEA is not a useful prognostic
marker in a subset of patients in which it was initially increased
above the normal levels. In contrast to our result Lee et al.21
reported that elevated preoperative CEA levels are associated
with tumor burden and showed independent prognostic
significance.
In conclusion: Serum CYFRA21-1 is highly elevated in
Egyptian breast cancer patients in comparison with controls
and adds significant improvement in breast cancer diagnosissuperior to CA15.3 and CEA. Moreover, the measurement
of serum CYFRA 21-1 may be useful for detecting disease
relapse and for assessing surgical and chemotherapeutic effi-
cacy. Further prospective studies using greater numbers of
patients are required to confirm our findings.
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